Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
24/7 Wall St5d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Hosted on MSN3h
Ashwini Vaishnaw's 4-point strategy for India's economy
IT Minister Ashwini Vaishnaw outlined India's economic strategy based on four pillars -- public investment, focus on manufacturing and innovation, inclusive growth, and simplification.
Investors lose their appetite for the obesity trade
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiations
Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated ...
The Financial Express4d
Weight loss pills Ozempic, Wegovy and Trizepatide enter Indian market
Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...
LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.